Search | OpenScholar

Search results

356 results found

CD 140 Study Group. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol 2012;35:208-14.

Publication: Journal Article

Charles, D, A Brashear, RA Hauser, Li HI, LM Boo, and MF Brin. 2012. “CD 140 Study Group. Efficacy, Tolerability, and Immunogenicity of Onabotulinumtoxina in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical Dystonia. Clin Neuropharmacol 2012;35:208-14.”. Clin Neuropharmacol.

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 2012;79:163-9.

Publication: Journal Article

LeWitt, PA, RA Hauser, M Lu, AP Nicholas, W Weiner, N Coppard, M Leinonen, and JM Savola. 2012. “Randomized Clinical Trial of Fipamezole for Dyskinesia in Parkinson Disease (FJORD Study). Neurology 2012;79:163-9.”. Neurology.

A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. Parkinsons Dis 2012;1-8.

Publication: Journal Article

Morelli, M, F Blandini, N Simola, and RA Hauser. 2012. “A(2A) Receptor Antagonism and Dyskinesia in Parkinson’s Disease. Parkinsons Dis 2012;1-8.”. Parkinsons Dis.

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 2011;10:221-9.

Publication: Journal Article

Hauser, RA, M Cantillon, E Pourcher, F Micheli, V Mok, M Onofrj, S Huyck, and K Wolski. 2011. “Preladenant in Patients With Parkinson’s Disease and Motor Fluctuations: A Phase 2, Double-Blind, Randomised Trial. Lancet Neurol 2011;10:221-9.”. Lancet Neurol.

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease. Mov Disord 2014;29:1028-34.

Publication: Journal Article

Hauser, RA, D Silver, A Choudhry, E Eyal, and S Isaacson. 2014. “Randomized, Controlled Trial of Rasagiline As an Add-on to Dopamine Agonists in Parkinson’s Disease. Mov Disord 2014;29:1028-34.”. Mov Disord.

Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. Mov Disord 2011;26:1464-76.

Publication: Journal Article

Sampaio, C, J Bronzova, RA Hauser, AE Lang, O Rascol, SV Van De Witte, and AA Theeuwes. 2011. “Pardoprunox in Early Parkinson’s Disease: Results from 2 Large, Randomized Double-Blind Trials. Mov Disord 2011;26:1464-76.”. Mov Disord.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

Publication: Journal Article

Rascol, O, CJ Fitzer-Attas, RA Hauser, J Jankovic, A Lang, JW Langston, E Melamed, et al. 2011. “A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson’s Disease (the ADAGIO Study): Prespecified and Post-Hoc Analyses of the Need for Additional Therapies, Changes in UPDRS Scores, and Non-Motor Outcomes”. Lancet Neurol.

Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.

Publication: Journal Article

Friedman, JH, P Agarwal, R Alcalay, KJ Black, KL Chou, L Cote, P Dayalu, et al. 2011. “Clinical Vignettes in Parkinson’s Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours.”. Int J Neurosci.

Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.

Publication: Journal Article

Hauser, RA, AL Ellenbogen, LV Metman, A Hsu, MJ O’Connell, NB Modi, HM Yao, SH Kell, and SK Gupta. 2011. “Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson’s Disease.”. Mov Disord.

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.

Publication: Journal Article

Brin, MF, CL Comella, J Jankovic, F Lai, M Naumann, and BoNTA Study Group. 2008. “Long-Term Treatment With Botulinum Toxin Type A in Cervical Dystonia Has Low Immunogenicity by Mouse Protection Assay.”. Mov Disord.